Preliminary data from phase II the GALAHAD study showed that approximately 40 percent of patients with DRD in BRCA1/2 receiving treatment with niraparib (300 mg daily) demonstrated an objective response, defined by the Response Evaluation Criteria in Solid Tumors guideline, version 1.1, as a standard measure of tumor response.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
